Close Menu

NEW YORK – A new study spelling out the range of mutations that can arise in colorectal cancer (CRC) in response to targeted treatments suggests that the tumors increase their mutation rate to become resistant.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

May
06
Sponsored by
Isoplexis

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.